Zevalin News and Research

RSS
Zevalin is a monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment and detection of other types of B-cell tumors. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Ibritumomab binds to the protein called CD20, which is found on B cells. It is linked to the compound tiuxetan. This allows certain radioisotopes to be attached before it is given to a patient. It is a type of monoclonal antibody-chelator conjugate. Also called ibritumomab tiuxetan.
Spectrum Pharmaceuticals to present ZEVALIN data at ASH Meeting

Spectrum Pharmaceuticals to present ZEVALIN data at ASH Meeting

Spectrum Pharmaceuticals ranked #23 on Deloitte's Technology Fast 500

Spectrum Pharmaceuticals ranked #23 on Deloitte's Technology Fast 500

Spectrum Pharmaceuticals receives $977,900 grant under QTDP program

Spectrum Pharmaceuticals receives $977,900 grant under QTDP program

Spectrum submits complete response to FDA's CRL for FUSILEV to treat colorectal cancer

Spectrum submits complete response to FDA's CRL for FUSILEV to treat colorectal cancer

Cell Therapeutics 2010 third quarter total net operating expense decreases 52% to $13.0 million

Cell Therapeutics 2010 third quarter total net operating expense decreases 52% to $13.0 million

NIH awards Phase I SBIR grant to develop Generic Antibodies for cancer

NIH awards Phase I SBIR grant to develop Generic Antibodies for cancer

AMIC signs world-wide license for brachytherapy seed with fast-dissolving matrix

AMIC signs world-wide license for brachytherapy seed with fast-dissolving matrix

Roche's MabThera continues to dwarf recently launched monoclonal antibodies: Report

Roche's MabThera continues to dwarf recently launched monoclonal antibodies: Report

CTI second-quarter total net operating expenses decrease to $20.0 million

CTI second-quarter total net operating expenses decrease to $20.0 million

Spectrum Pharmaceuticals adjourns Annual Meeting of Shareholders to July 1, 2010

Spectrum Pharmaceuticals adjourns Annual Meeting of Shareholders to July 1, 2010

Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010

Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010

PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting

PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting

Investment report on Spectrum Pharmaceuticals

Investment report on Spectrum Pharmaceuticals

CTI receives positive reception from EMEA clinical experts for pixantrone MAA

CTI receives positive reception from EMEA clinical experts for pixantrone MAA

MicroStockProfit.com announces investment report featuring Cell Therapeutics

MicroStockProfit.com announces investment report featuring Cell Therapeutics

BeaconEquity.com releases investment report on Cell Therapeutics

BeaconEquity.com releases investment report on Cell Therapeutics

Investment report on Spectrum Pharmaceuticals from BeaconEquity.com

Investment report on Spectrum Pharmaceuticals from BeaconEquity.com

Spectrum Pharmaceuticals reports $15.7M revenue from ZEVALIN sales in 2009

Spectrum Pharmaceuticals reports $15.7M revenue from ZEVALIN sales in 2009

First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat

First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat

BeaconEquity.com: CTIC' total net operating expenses for fourth-quarter of 2009 are $26.2M

BeaconEquity.com: CTIC' total net operating expenses for fourth-quarter of 2009 are $26.2M